AKER - Akers Biosciences, Inc.
| Previous Close | 1.2400 |
| Open | 1.2300 |
| Bid | 1.16 x 1000 |
| Ask | 1.27 x 900 |
| Day's Range | 1.1256 - 1.2300 |
| 52 Week Range | 0.9760 - 7.8400 |
| Volume | 161,135 |
| Avg. Volume | 856,303 |
| Market Cap | 20.475M |
| Beta (3Y Monthly) | -3.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.30 |
| Earnings Date | Nov 13, 2018 - Nov 19, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- Yahoo Finance Video•27 days ago
Apple shares down after cutting production orders for all three iphone models
Yahoo Finance's Julie Hyman highlights todays stocks on the move in midday trading.
- GlobeNewswire•17 days ago
Market Trends Toward New Normal in Gartner, CONVERGEONE HLD, Syros Pharmaceuticals, Akers Biosciences, Edge Therapeutics, and Cracker Barrel Old Country Store — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Markit•18 days agoSee what the IHS Markit Score report has to say about Akers Biosciences Inc.
Short interest is moderate for AKER with between 5 and 10% of shares outstanding currently on loan. The net inflows of $251 million over the last one-month into ETFs that hold AKER are not among the highest of the last year and have been slowing.
- Benzinga•26 days ago
This Tiny Biotech Firm Is Weighing An Entrance Into Cannabis
Akers Biosciences, Inc. (NASDAQ: AKER)'s stock was trending on Benzinga Pro Tuesday, with shares of the microcap trading on 40-percent higher than average volume. The stock's decline — it was down 11.7 percent at $1.54 at the time of publication Tuesday — follows the 42.28-percent jump the shares registered Monday following an announcement that the company could enter the cannabis industry. What Is Akers? Akers Biosciences develops and manufactures rapid screening and testing products for health care providers and consumers.
Markit•27 days agoSee what the IHS Markit Score report has to say about Akers Biosciences Inc.
Short interest is moderate for AKER with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on November 16.
- ACCESSWIRE•27 days ago
Today’s Research Reports on Stocks to Watch: Akers Biosciences and Align Technology
NEW YORK, NY / ACCESSWIRE / November 20, 2018 / While Akers Biosciences shares were exploding on the news that the company is considering the cannabis industry, shares of Align Technology were plummeting on a pessimistic highlight of the company in the Wall Street Journal from over the weekend. Align Technology, Inc. Akers Biosciences, Inc. shares closed up 42.28% on Monday on tremendous trading volume of nearly 15.4 million shares traded.
- The Wall Street Journal•27 days ago
[$$] Biotech Learns the Magic Word
What role cannabis should play in medicine is still an open question. The company also noted in its news release that Akers directors met with a number of cannabis companies at the MJBizCon conference in Las Vegas.
- MarketWatch•27 days ago
Failing biotech company mentions pot business, stock soars 70%
Failing biotech company Akers Biosciences Inc. stock soared 70% Monday following the company's announcement that it was looking into "business combinations" in the cannabis sector after a trip to a pot conference in Las Vegas last week. Akers offered no details about how it planned to enter the marijuana business. The company has been sued by shareholders in the past for publishing false and misleading information, downplaying weaknesses in its financial reporting standards and improperly recognizing revenue in 2017. Akers said in May that it was delaying its first-quarter accounts to the Securities and Exchange Commission while it reviewed them, and investigated whether previous reports would need to be amended. The SEC has previously issued warnings about potential scams in the marijuana industry and other companies have issued similar announcements, prompting large stock moves even though no business or product eventually emerges. Currently 11% of the stock is shorted down from 55% in March, according to FactSet. Akers stock has nearly doubled this year, as the S&P 500 index gained 2.3%.
- American City Business Journals•27 days ago
South Jersey medical device firm exploring cannabis industry combination
The Thorofare, N.J., company which began exploring "strategic alternatives" earlier this month has hired a legal advisor to advise it on potential business combinations in the cannabis industry.
- GlobeNewswire•27 days ago
Akers Biosciences Exploring Potential Business Combinations in Alternative Sectors Including Cannabis Industry
Akers Biosciences, Inc. (AKER) (AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, is pleased to provide an update on the process announced on November 7, 2018 to evaluate strategic alternatives to maximize shareholder value. The Company can now confirm that this process will consider a range of potential strategic alternatives including, but not limited to, business combinations in alternative sectors including cannabis related industries. Members of the Company’s board have recently met with a number of companies in cannabis related industries at the MJBizCon conference in Las Vegas, Nevada.
- GlobeNewswire•last month
Akers Biosciences Announces Q3 2018 Earnings
Sales of Flagship PIFA Heparin PF/4 Rapid Assay Products Up 16% over Q3 2017; Company Continuing to Evaluate Strategic Alternatives to Maximize Shareholder Value THOROFARE,.
- American City Business Journals•last month
South Jersey medical-device company exploring 'strategic alternatives'
Akers BioSciences is also implementing a one-for-eight reverse stock split to stay in compliance with NASDAQ listing requirements.
- GlobeNewswire•last month
Akers Biosciences Announces Intention to Explore Strategic Alternatives to Maximize Shareholder Value
Akers Biosciences, Inc. (AKER) (AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces that the Board of Directors has initiated a process to evaluate strategic alternatives to maximize shareholder value. This process will consider a range of potential strategic alternatives including, but not limited to, business combinations, while simultaneously supporting the Company’s management and employees in the execution of the Company’s current business activities. The Company does not plan to disclose or comment on developments regarding the strategic review process until it is complete or further disclosure is deemed appropriate.
Markit•2 months agoSee what the IHS Markit Score report has to say about Akers Biosciences Inc.
Akers Biosciences Inc NASDAQ:AKER
Markit•2 months agoSee what the IHS Markit Score report has to say about Akers Biosciences Inc.
Akers Biosciences Inc NASDAQ:AKER
- GlobeNewswire•2 months ago
Market Trends Toward New Normal in PTC Therapeutics, AeroVironment, Autodesk, Coca-Cola Bottling Co. Consolidated, Akers Biosciences, and TEGNA — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- American City Business Journals•2 months ago
South Jersey medical device company makes CEO switch, settles lawsuit
For the second time in the past three years, Akers BioSciences has a new CEO. The South Jersey medical device company announced Monday that John J. Gormally resigned as CEO of Akers Bio, and as a member of the board, effective immediately. Akers Bio did not provide any additional details on his departure other than to say: “The board of directors thanks Mr. Gormally for his contribution to the company since joining Akers Bio [as CEO] in 2015 and its board of directors in 2017.” Gormally replaced the company's co-founder and namesake, Dr. Raymond Akers, as CEO in late 2015.
- GlobeNewswire•2 months ago
Akers Biosciences Announces a Leadership Change, Strategic Update, Legal Settlement and an AIM Update
Akers Biosciences, Inc. (AKER) (AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces a leadership change, an update to the Company’s business strategy, the settlement of its lawsuit with Pulse Health LLC (“Pulse Health”) and the resignation of its Nominated Adviser on the London Stock Exchange’s AIM market. Howard R. Yeaton has been appointed to the position of Chief Executive Officer effective immediately.
Markit•3 months agoSee what the IHS Markit Score report has to say about Akers Biosciences Inc.
Short interest is moderate for AKER with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
Markit•4 months agoSee what the IHS Markit Score report has to say about Akers Biosciences Inc.
Short interest is moderate for AKER with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- ACCESSWIRE•4 months ago
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Akers Biosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 13, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akers Biosciences, Inc. ("Akers" or the "Company") (NASDAQ: AKER) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- ACCESSWIRE•4 months ago
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akers Biosciences, Inc. (AKER) & Lead Plaintiff Deadline: August 13, 2018
NEW YORK, NY / ACCESSWIRE / August 13, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Akers Biosciences, Inc. ("Akers" or the "Company") (AKER) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Akers securities between May 15, 2017 through June 5, 2018, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
- ACCESSWIRE•4 months ago
DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Akers Biosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 12, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akers Biosciences, Inc. ("Akers" or the "Company") (NASDAQ: AKER) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
